Chiglitazar Added to Metformin for Type 2 Diabetes

  • STATUS
    Recruiting
  • End date
    Mar 31, 2023
  • participants needed
    519
  • sponsor
    Chipscreen Biosciences, Ltd.
Updated on 29 April 2022
fasting
metformin
hemoglobin a1c

Summary

The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.

Description

This clinical trial is a multi-center, randomized, double-blind, placebo parallel control design, and uses superiority test to determine whether the experimental group is superior to the control group in terms of main efficacy endpoints.

Details
Condition Type 2 Diabetes
Treatment Placebo, Metformin Hydrochloride, Chiglitazar 32mg, Chiglitazar 48mg
Clinical Study IdentifierNCT04807348
SponsorChipscreen Biosciences, Ltd.
Last Modified on29 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

) Provide a signed and dated informed consent form
) Men and women aged ≥ 18 years and ≤ 75 years
) According to the World Health Organization ( the WHO ) 1999 criteria for the diagnosis of type 2 diabetes
) After metformin stable dose monotherapy (≥1500 mg/day or maximum tolerated dose, but the maximum tolerated dose not < l000 mg/day) for at least 8 weeks
) The local HbA1c value during the screening period: 7.5% ≤ HbA1c ≤ 11%
) The HbA1c value of the central laboratory before randomization: 7.0% ≤ HbA1c ≤ 10.5%
) BMI ≥ 18.5 kg/m2 and ≤ 35 kg/m 2
) Fasting C- peptide ≥ 0.5 nmol/L
) Women of Childbearing Potential ( WOCBP ) should take reliable contraceptive measures at least 1 month before the screening, during the entire trial, and within 3 months after completing the trial; male subjects should take reliable contraceptive measures to avoid making their sexual partners to pregnant during the entire trial and within 3 months after the trial

Exclusion Criteria

) Type 1 diabetes
) Pregnancy or lactation
) The New York Heart Association (NYHA ) defines congestive heart failure as grade III or IV
) Significant history of cardiovascular and cerebrovascular diseases within 6 months before screening, defined as myocardial infarction, coronary artery bypass graft or angioplasty, valvular disease or repair, unstable angina, transient brain Ischemic attack, or cerebrovascular accident
) Suffered from malignant tumors (except cured basal cell carcinoma) within 5 years before screening
) Edema of lower limbs or edema of the whole body
) Moderate to severe renal insufficiency [ Calculated eGFR<60 ml/ ( min1.73m2 ) using CKD - EPI formula ]
) urinary albumin-to-creatinine ratio of > 300 mg /g
) Triglyceride> 5.6 mmol /L
) Active liver disease and /or obvious liver function abnormalities, defined as AST>2.5 times the upper limit of normal value and/or ALT>2.5 times the upper limit of normal value and/or total bilirubin >1.5 times the normal value Upper limit
) Clinically significant arrhythmias in the electrocardiogram examination and treatment or intervention are required. The investigator judges that it is not suitable to participate in this clinical trial
) Human immunodeficiency virus (HIV) antibody-positive; Treponema pallidum antibody positive; positive hepatitis B surface antigen and HBV DNA quantification values were higher than the upper; HCV antibodies and HCV RNA quantification values were higher than the upper
) History of illegal drug abuse within 12 months before screening
) Participated in other clinical trials within 90 days before screening
) Donated whole blood, plasma, or platelets within 3 months before screening
) Before randomization, the investigator judged that the subjects had poor compliance with the study protocol or drug treatment, defined as the subjects taking less than 80% or more than 120% of the prescribed dose of chiglitazar/ placebo or metformin
) The investigator judged that it is not suitable to participate in this clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note